FDA & Government News

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

Share

  • 1

    FDA approval for icotrokinra for moderate-to-severe plaque psoriasis.

  • 2

    Approved for patients 12 years and older, weighing at least 40 kg.

  • 3

    New oral alternative to injectable therapies.

  • 4

    Phase 3 trials included around 2,500 patients.

  • 5

    70% of patients achieved significant skin clearance.

  • 6

    Common side effects: headache, nausea, cough, fatigue.

  • 7

    Monitoring for infections, including tuberculosis, is advised.

  • 8

    Impacts quality of life for over 8 million affected in the US.

Original Source(s)

FDA Approves New Oral Option for Plaque Psoriasis

  • by Kathryn Wighton

  • March 18, 2026

Related Content

Can Peptides Improve Skin Aging?

Systematic review reports gains in hydration, brightness, and wrinkles, with stronger evidence for oral vs topical formulations

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

Sunscreen Costs Vary Up to 36-Fold

Economic analysis finds large differences in the annual cost of recommended sunscreen use depending on product price and clothing-based sun protection strategies